254 related articles for article (PubMed ID: 15185230)
1. Restored immune response to an MHC-II-Restricted antigen in tumor-bearing hosts after elimination of regulatory T cells.
Nicholl M; Lodge A; Brown I; Sugg SL; Shilyansky J
J Pediatr Surg; 2004 Jun; 39(6):941-6; discussion 941-6. PubMed ID: 15185230
[TBL] [Abstract][Full Text] [Related]
2. Demonstration of strong enterobacterial reactivity of CD4+CD25- T cells from conventional and germ-free mice which is counter-regulated by CD4+CD25+ T cells.
Gad M; Pedersen AE; Kristensen NN; Claesson MH
Eur J Immunol; 2004 Mar; 34(3):695-704. PubMed ID: 14991599
[TBL] [Abstract][Full Text] [Related]
3. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.
Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ
J Immunol; 2003 Dec; 171(11):5931-9. PubMed ID: 14634104
[TBL] [Abstract][Full Text] [Related]
4. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
5. Complementary role of CD4+CD25+ regulatory T cells and TGF-beta in oral tolerance.
Chung Y; Lee SH; Kim DH; Kang CY
J Leukoc Biol; 2005 Jun; 77(6):906-13. PubMed ID: 15758078
[TBL] [Abstract][Full Text] [Related]
6. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.
Tanaka H; Tanaka J; Kjaergaard J; Shu S
J Immunother; 2002; 25(3):207-17. PubMed ID: 12000862
[TBL] [Abstract][Full Text] [Related]
7. CD4+CD25+ cell depletion from the normal CD4+ T cell pool prevents tolerance toward the intestinal flora and leads to chronic colitis in immunodeficient mice.
Veltkamp C; Ruhwald R; Giesem T; Autschbach F; Kaden I; Veltkamp R; Sartor RB; Stremmel W
Inflamm Bowel Dis; 2006 Jun; 12(6):437-46. PubMed ID: 16775487
[TBL] [Abstract][Full Text] [Related]
8. Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.
Peng L; Kjaergäard J; Plautz GE; Awad M; Drazba JA; Shu S; Cohen PA
J Immunol; 2002 Nov; 169(9):4811-21. PubMed ID: 12391191
[TBL] [Abstract][Full Text] [Related]
9. Role for thymic and splenic regulatory CD4+ T cells induced by donor dendritic cells in allograft tolerance by LF15-0195 treatment.
Chiffoleau E; Bériou G; Dutartre P; Usal C; Soulillou JP; Cuturi MC
J Immunol; 2002 May; 168(10):5058-69. PubMed ID: 11994458
[TBL] [Abstract][Full Text] [Related]
10. Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals.
Cavani A; Nasorri F; Ottaviani C; Sebastiani S; De Pità O; Girolomoni G
J Immunol; 2003 Dec; 171(11):5760-8. PubMed ID: 14634084
[TBL] [Abstract][Full Text] [Related]
11. Identification of a CD4+CD25+ T cell subset committed in vivo to suppress antigen-specific T cell responses without additional stimulation.
Nolte-'t Hoen EN; Wagenaar-Hilbers JP; Boot EP; Lin CH; Arkesteijn GJ; van Eden W; Taams LS; Wauben MH
Eur J Immunol; 2004 Nov; 34(11):3016-27. PubMed ID: 15376196
[TBL] [Abstract][Full Text] [Related]
12. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
Frey AB; Cestari S
Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
Wang LX; Chen BG; Plautz GE
J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
[TBL] [Abstract][Full Text] [Related]
14. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
15. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.
Plautz GE; Mukai S; Cohen PA; Shu S
J Immunol; 2000 Oct; 165(7):3656-62. PubMed ID: 11034369
[TBL] [Abstract][Full Text] [Related]
16. Early events in peripheral regulatory T cell induction via the nasal mucosa.
Unger WW; Hauet-Broere F; Jansen W; van Berkel LA; Kraal G; Samsom JN
J Immunol; 2003 Nov; 171(9):4592-603. PubMed ID: 14568933
[TBL] [Abstract][Full Text] [Related]
17. CD4+ T cells cooperate with macrophages for specific elimination of MHC class II-negative cancer cells.
Corthay A
Adv Exp Med Biol; 2007; 590():195-208. PubMed ID: 17191387
[No Abstract] [Full Text] [Related]
18. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.
McMenamin C; Holt PG
J Exp Med; 1993 Sep; 178(3):889-99. PubMed ID: 8102390
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy with tumor cell lysate-pulsed CD8α+ dendritic cells modulates intra-tumor and spleen lymphocyte subpopulations.
Azadmehr A; Pourfathollah AA; Amirghofran Z; Hassan ZM; Moazzeni SM
Neoplasma; 2013; 60(5):525-32. PubMed ID: 23790171
[TBL] [Abstract][Full Text] [Related]
20. Increased numbers and suppressive activity of regulatory CD25(+)CD4(+) T lymphocytes in the absence of CD4 engagement by MHC class II molecules.
Shen X; Niu C; König R
Cell Immunol; 2013 Apr; 282(2):117-28. PubMed ID: 23770721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
